Tianjin Kilo Pharmaceutical Receives FDA Warning Letter After Remote Records Review

Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. is now operating under an FDA warning letter issued August 6, 2026, after a remote records review under section 704(a)(4) of the FD&C Act identified significant CGMP deviations at its Tianjin API manufacturing facility. For supply chain and QA leads sourcing APIs from China, the case is a direct signal that FDA is conducting substantive compliance assessments without physical site presence.

The review was triggered by a records request dated July 7, 2025. FDA's Center for Drug Evaluation and Research (CDER) found that Tianjin Kilo distributed APIs to the U.S. market without adequate process validation. When asked to provide process validation summary reports for all U.S.-marketed APIs, the firm indicated the products were still in development and that formal SOPs had not been finalized. Under 21 CFR Part 211 and ICH Q7 expectations for API manufacturers, distributing commercial product absent validated processes constitutes adulteration under section 501(a)(2)(B) of the FD&C Act.

Compounding the CGMP findings, FDA identified drug listing failures in the firm's eDRLS submissions. Tianjin Kilo did not provide required listing information for demecarium bromide and chlorambucil, rendering both drugs misbranded under section 502(o) and prohibiting their introduction into U.S. interstate commerce under section 301(a). The dual nature of the violations, manufacturing controls and registration compliance, broadens the regulatory exposure beyond a single corrective action stream.

For procurement and supplier qualification teams, the mechanism here carries operational weight. FDA's 704(a)(4) authority allows the agency to request records from foreign facilities and base enforcement action on documentary review alone, without an on-site inspection. This warning letter, issued against FEI 3012560989, confirms that overseas API suppliers are not insulated from enforcement by geography or inspection scheduling constraints.

Firms currently qualifying Tianjin Kilo as a supplier, or holding approved drug applications that reference its APIs, will need to assess whether their supplier qualification programs and CAPA frameworks adequately account for remote-review-triggered enforcement actions of this type.

FDA's warning letter requires prompt corrective action and reserves the right to pursue further regulatory measures without additional notice, with the adequacy of Tianjin Kilo's response likely to determine the timeline for any import alert consideration.

Source: FDA Center for Drug Evaluation and Research (CDER) via FDA.gov Warning Letters database, August 18, 2026. Warning letter reference number 320-26-110, dated August 6, 2026.